Grant Funds Development of a Novel Malaria Vaccine - - BioPharm International

ADVERTISEMENT

Grant Funds Development of a Novel Malaria Vaccine



iQur, the UK biotechnology company, and the Edward Jenner Institute for Vaccine Research (University of Oxford) announced that that they will receive a grant of £152,000 ($201,523) from the Technology Strategy Board’s Biocatalyst fund to develop a novel malaria vaccine. The parties to develop a novel virus-like particle (VLP) based vaccine using iQur’s proprietary tandem core technology.

A proof of concept study will be carried out in which iQur will make VLPs carrying specific malaria targets that have been identified by the Jenner. If the project is successful, further funding will be sought to progress the targets into a clinical trial.

Source: iQur

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines

Click here